# Aminoalkylthio hydroxydibenzoxepins, a process for their preparation and their use as medicaments

## Claims
Claims 1. A compound of the formula IEMI7.1 wherein R, is hydrogen, loweralkyl of 1 to 6 carbon atoms or a group of the formula EMI8.1 wherein X is hydrogen, halogen, loweralkyl of 1 to 6 carbon atoms, loweralkoxy of 1 to 6 carbon atoms, trifluoromethyl or nitro R2 is loweralkyl of 1 to 6 carbon atoms Y is hydrogen, halogen, hydroxy, trifluoromethyl, loweralkyl of 1 to 6 carbon atoms, loweralkoxy of 1 to 6 carbon atoms, loweralkylthio of 1 to 6 carbon atoms, loweralkylsulfinyl of 1 to 6 carbon atoms, loweralkylsulfony of 1 to 6 carbon atoms, amino or nitro and n is 2, 3 or 4, the optical antipodes thereof or a pharmaceutically acceptable salt thereof. 2. A compound according to claim 1 where R, is hydrogen Y is halogen and n is 2. 3. A compound according to claim 1 wherein R, is a group of the formulaEMI8.2 wherein X is hydrogen Y is halogen and n is 2. 4. The compound according to claim 2 which is 2 fluoro 7 hydroxy 1 1 P methylamino ethylthio dibenz b,f oxepin. 5. The compound according to. claim 2 which is 2 fluoro 8 hydroxy 1 1 8 methylamino ethylthio dibenz b,f oxepin. 6. The compound according to claim 3 which is 2fluoro 7 hydroxy 1 1 ss N methyl N phneoxycarbonylamino ethylthio dibenz b,f oxepin. 7. The compound according to claim 3 which is 2 fiuoro 8 hydroxy 1 1 ss N methyl N phenoxycarbonylamino ethylthio dibenz b,f oxepin. 8. A process for the preparation of a compound of the formula IEMI8.3 wherein R, is hydrogen, loweralkyl of 1 to 6 carbon atoms or a group of the formulaEMI8.4 wherein X is hydrogen, halogen, loweralkyl of 1 to 6 carbon atoms, loweralkoxy of 1 to 6 carbon atoms, trifluoromethyl or nitro R2 is loweralkyl of 1 to 6 carbon atoms Y is hydrogen, halogen, hydroxy, trifluoromethyl, loweralkyl of 1 to 6 carbon atoms. loweralkoxy of 1 to 6 carbon atoms, loweralkylthio of 1 to 6 carbon atoms, loweralkylsulfinyl of 1 to 6 carbon atoms, ioweralkylsulfonyl of 1 to 6 carbon atoms, amino or nitro and n is 2, 3, or 4, the optical antipodes thereof, or a pharmaceutically acceptable salt thereof, which comprises dealkylating a compound of the formula IIEMI9.1 wherein Y is as defined above, R is loweralkyl of 1 to 6 carbon atoms, R, is loweralkyl of 1 to 6 cabon atoms or a group of the formulaEMI9.2 where X is as defined above, and R2 is loweralkyl of 1 to 6 carbon atoms, to provide a compound of the formula IEMI9.3 wherein Y, R, and R2 are as defined above, and optionally hydrolyzing a compound of the formula I wherein R, is a group of the formulaEMI9.4 and R2 and Y are as defined above, to provide a compound of the formula I wherein Rt is hydrogen and R2 and Y are as defined above, and optionally preparing a pharmacologically acceptable salt thereof. 9. The process as defined in claim 8 wherein the dealkylation of the compound of the formula II is performed by treating the compound of the formulaII with a boron trihalide of the formula BHal3 in a halocarbon solvent. 10. The process as defined in claim 9 wherein boron tribromide in a halogenated alkane as a solvent is used. 11. A pharmaceutical composition which comprises as active ingredient a compound as defined in claim 1 in association with a pharmaceutically acceptable carrier. 12. Use of a compound as defined in claim 1 for the preparation of a medicament having antidepressant and or analgesic activity. Claims for contracting state AT 1. A process for the preparation of a compound of the formula IEMI10.1 wherein R, is hydrogen, loweralkyl of 1 to 6 carbon atoms or a group of the formulaEMI10.2 wherein X is hydrogen, halogen, loweralkyl of 1 to 6 carbon atoms, loweralkoxy of 1 to 6 carbon atoms, trifluoromethyl or nitro R2 is loweralkyl of 1 to 6 carbon atoms Y is hydrogen, halogen, hydroxy, trifluoromethyl, loweralkyl of 1 to 6 carbon atoms, loweralkoxy of 1 to 6 carbon atoms, loweralkylthio of 1 to 6 carbon atoms, loweralkylsulfinyl of 1 to 6 carbon atoms, loweralkylsulfonyi of 1 to 6 carbon atoms, amino or nitro and n is 2, 3, or 4, the optical antipodes thereof, or a pharmaceutically acceptable salt thereof, which comprises dealkylating a compound of the formula IIEMI10.3 wherein Y is as defined above, R is loweralkyl of 1 to 6 carbon atoms, R, is loweralkyl of 1 to 6 cabon atoms or a group of the formula EMI11.1 where X is as defined above, and R2 is loweralkyl of 1 to 6 carbon atoms, to provide a compound of the formula IEMI11.2 wherein Y, R1 and R2 are as defined above, and optionally hydrolyzing a compound of the formula I wherein R, is a group of the formulaEMI11.3 and R2 and Y are as defined above, to provide a compound of the formula I wherein R, is hydrogen and R2 and Y are as defined above, and optionally preparing a pharmacologically acceptable salt thereof. 2. The process as defined in claim 8 wherein the dealkylation of the compound of the formula Il is performed by treating the compound of the formulaII with a boron trihalide of the formula BHal in a halocarbon solvent. 3. The process as defined in claim 9 wherein boron tribromide in a halogenerated alkane as a solvent is used. 4. The process as defined in claims 1 3, wherein a compound of the formula I is prepared, where R is hydrogen, Y is halogen and n is 2. 5. The process as defined in claims 1 3, wherein a compound of the formula I is prepared where Y is halogen, n is 2 and R, is a group of the formulaEMI11.4 where X is hydrogen. 6. The process as defined in claim 4 wherein the compound 2 fiuoro 7 hydroxy 11 ,8 methylaminoF ethylthio dibenz b, f oxepin is prepared. 7. The process as defined in claim 4 wherein the compound 2 fluoro 8 hydroxy 11 ,6 methylamino ethylthio dibenz b,f oxepin is prepared. 8. The process as defined in claim 5 wherein the compound 2 fluoro 7 hydroxy 1 1 ss N methyl N phenoxycarbonylamino ethylthio dibenz b,f oxepin is prepared. 9. The process as defined in claim 5 wherein the compound 2 fluoro 8 hydroxy 1 1 ss N methyl N phenoxycarbonylamino ethylthio dibenz b,f oxepin is prepared.

## Description
Aminoalkylthio hydroxydibenzoxepins, a process for their preparation and their use as medicaments The present invention relates to novel aminoalkylthio hydroxydibenzoxepins. More particularly, the present invention relates to aminoalkylthio hydroxydibenzoxepins of the formulaEMI1.1 wherein R, is hydrogen, loweralkyl of 1 to 6 carbon atoms or a group of the formulaEMI1.2 wherein X is hydrogen, halogen, loweralkyl of 1 to 6 carbon atoms, loweralkoxy of 1 to 6 carbon atoms, trifluoromethyl or nitro R2 is loweralkyl of 1 to 6 carbon atoms Y is hydrogen, halogen, hydroxy, trifluoromethyl, loweralkyl of 1 to 6 carbon atoms, loweralkoxy of 1 to 6 carbon atoms, loweralkylthio of 1 to 6 carbon atoms, loweralkylsulfinyl of 1 to 6 carbon atoms, loweralkylsulfonyl of 1 to 6 carbon atoms, amino or nitro and n is 2, 3, or 4, the optical antipodes thereof, or a pharmaceutically acceptable salt thereof, which are useful for treating depression and alleviating pain, alone or in combination with inert adjutants. Preferred aminoalkylthio hydroxydibenzoxepins of the present invention are those wherein R, is hydrogen Y is halogen and n is 2. Included within the aminoalkylthioF hydroxydibenzoxepins of the present invention are phenoxycarbonylaminoalkylthio hydroxydibenzoxepins of formula 1 wherein R, is a group of the formulaEMI1.3 wherein X is as above, as intermediates for the preparation of compounds of the present invention wherein R, is hydrogen. Preferred phenoxycarbonylaminoalkylthio hydroxydibenzoxepins of the present invention are those wherein X is hydrogen, Y is halogen and n is 2. As used through the specification and appended claims, the term alkyl refers to a straight or branched chain hydrocarbon radical containing no unsaturation and having 1 to 10 carbon atoms such as methyl, ethyl, 1 propyl, 2 propyl, 1 butyl, 1pentyl, 2 pentyl, 3 hexyl, 4 heptyl, 2 octyl, 3 nonyl, 4 decyl and the like the term alkanol refers to a compound formed by a combination of an alkyl group and a hydroxy radical. Examples of alkanols are methanol, ethanol, 1 and 2 propanol, 1,2dimethylethanol, hexanol, octanol, decanol and the like. The term alkoxy refers to a group formed by removal of a hydrogen function from the hydroxy group of an alkanol. Exampies of alkoxy groups are methoxy, ethoxy, 1 and 2 propoxy, 1,2dimethylethoxy, hexoxy, octoxy, decoxy and the like. The term halogen refers to a member of the family, fluoro, chloro, bromo, and iodo.The term lower as applied to any of the aforementioned groups refers to a group having a carbon skeleton containing up to and including 6 carbon atoms. The compounds of the present invention which lack an element of symmetry exist as optical antipodes and as the racemic forms thereof. The optical antipode may be prepared from the corresponding racemic forms by standard optical resolution techniques, involving, for example, the separation of diasteromeric salts of those instant compounds characterized by the presence of a basic amino group and an optically active acid, or by the synthesis from optically active precursors. The present invention comprehends all optical isomers and racemic forms thereof of the compounds disclosed and claimed herein. The formulas of the compounds shown herein are intended to encompass all optical isomers of the compounds so depicted. The novel aminoalkylthio hydroxydibenzoxepins of the present invention wherein R, is hydrogen are synthesized by dealkylation of an alkoxy aminoalkylthio dibenzoxepin of formula 2EMI2.1 wherein R is loweralkyl, R2 is loweralkyl, and X, Y and n are as hereinbeforedescribed, the preparation of which is disclosed in European Patent No.000 2508, to afford an aminoalkylthio hydroxybenzoxepin of formula 3EMI2.2 wherein R2, X, Y, and n are as above, followed by hydrolysis of the phenoxycarbonyi group of 3 to provide a compound of formula 4EMI3.1 wherein R2, Y and n are as above. The dealkylation is conveniently performed by contacting an alkoxy compound of formula 2 with a boron trihalide of formula 5BHal3 5 wherein Hal is halogen in a halocarbon solvent.Among boron halides there may be mentioned boron triiodide, boron tribromide and boron trichioride. Boron tribromide is preferred. Among halocarbon solvents there may be mentioned dich loromethane, trichloromethane, 1,1 ,1 dichloroethane, 1,2 dichloroethane, and the like. Dichloromethane is referred. While the dealkylation temperature is not narrowly critical, it is preferred to conduct the reaction at a temperature within the range of about 0 to 500C, the most preferred temperatu.re being about 25 C. The hydrolysis of an N phenoxycarbonylalkylthio dibenzoxepin is accomplished by treating 3 with an alkali metal hydroxide such as lithium hydroxide, sodium hydroxide or potassium hydroxide in an aqueous alkanol such as methanol, ethanol, 1 for 2 propanol, 2,2dimethylethanol and the like, or an aqueous alkandiol such as 1,2 dihydroxyethane, 1,2 dihydroxypropane, 1,3 dihydroxypropane and the like. The conversion proceeds smoothly at moderate temperatures. However, when an alkandiol is utilized as the solvent, elevated temperatures within the range of about 1250 to about 175 C are employed to promote the reaction. Potassium hydroxide, aque ous 1,2 dihydroxyethane and the reaction temperatures of about 1500 to about 16500 are preferred. The novel aminoalkylthio hydroxydibenzoxepins of the present invention wherein R, is loweralkyl may be prepared, for example, by dealkylation of an alkoxy aminoalkylthio dibenzoxepin of formula 6 EMI4.1 wherein R, R1, and R2 are loweralkyl, and Y and n are as hereinbeforedescribed, the synthesis of which is described in U.S. Patent Application Docket No. AHO 80 ClP Cont CIP CIP, filed even date herewith, by the process for the conversion of a compound of formula 2 to a compound of formula 3 to provide an aminoalkylthio hydroxydibenzoxepin of formula ZEMI4.2 wherein R1 and R2 are loweralkyl and Y and n are as hereinbeforedescribed. The aminoalkylthio hydroxydibenzoxepins of the present invention are useful in the treatment of depression in mammals, as demonstrated by their ability to inhibit tetrabenazine induced depression in mice International Journal of Neuropharmacology 8, 73 1969 , a standard assay for the determination of antidepressant properties. Thus, for instance, the intraperitoneal dose at which 2 fluoro 8hydroxy 1 1 ,6 methylamino ethylthio dibenz bJ oxepin effects a 50 inhibition of tetrabenazineinduced ptosis EDso in mice is 3.3 mg kg of body weight, and the intraperitoneal dose at which 2fluoro 7 hydroxy 1 1 ,i methylamino ethylthio dibenz b,f oxepin effects an 89 inhibition of tetrabenazine induced ptosis in mice is 20 mg kg of body weight.Amitriptyline, a standard antidepressant, exhibits an EDso of 1.5, intraperitoneally, in this assay. Antidepressant response is achieved when the present aminoalkylthio hydroxydibenzoxepins are administered to a subject requiring such treatment as an effective oral, parenteral or intravenous dose of from 0.01 to 100 mg kg of body weight per day.A particularly effective amount is about 25 mg kg of body weight per day. It is to be understood, however, that for any particular subject, specific dosage regimens should be adjusted according to the individual need and the professional judgment of the person administering or supervising the administration of the aforesaid compound. It is to be further understood that the dosages set forth herein are exemplary only and that they do not, to any extent, limit the scope or practice of the invention. The aminoalkylthio hydroxydibenzoxepins of the present invention are also useful as analgetic agents due to their ability to alleviate pain in mammals. The analgetic utility of compounds of this invention is demonstrated in the phenyl quinone writhing assay in mice, a standard assay for analgesia Proc. Soc. Exptl. Biol. Med., 95 729 1957 1.Thus, for example, the subcutaneous dose effecting a 69 inhibition of writhing in mice in this assay is 20 mg kg of body weight for 2 fluoro 8hydroxy 1 1 ss methylamino ethylthio dibenz b,f oxepin and the subcutaneous dose effecting a 42 inhibition of writhing is 10 mg kg of body weight for 2 fiuoro 7 hydroxy 1 1 B methylamino ethylthio dibenz b, f oxepin.Propoxyphene, a standard analgetic, exhibits a calculated 50 inhibition of writhing at 3.9 mg kg of body weight by subcutaneous administration in this assay. Analgetic production is achieved when the present aminoalkylthio hydroxydibenzoxepins are administered to a subject requiring such treatment as an effective oral, parenteral or intravenous dose of from 0.01 to 100 mg kg of body weight per day.A particularly effective amount is about 25 mg kg of body weight per day. It is to be understood, however, that for any particular subject, specific dosage regimens should be adjusted according to the individual need and the professional judgement of the person administering of the administering of the aforesaid compound. It is to be further understood that the dosages set forth herein are exemplary only and that they do not, to any extent, limit the scope or practice of the invention. Additional aminoalkylthio hydroxydibenzoxepins of the invention include a S hydrnxy 2 trifiuornmethyl 1 1 z dimethylamino propylthio dibenz b,f oxepin b. 2 fluoro 8 hydroxy 1 1 ss N methyl N 4 chloro phenoxycarbonyl aminoE ethylthio dibenz b.f oxepin c. 2 fluoro 8 hydroxy 1 I Cu N methyl N 3 methyl phenoxycarbonyl aminoE propyl dibenz b,floxepin d. 2 fluoro 8 hydroxy 1 I CG N methyl N 2 methoxy phenoxycarbony amono butyl dibenz b,f oxepin e. 2 fluoro7 hydroxy 1 1 ss N methyl N 4 trifluoro methylphenoxycarbonyl aminol ethylthio dibenz b,f oxepin f. 2 fluoro 7 hydroxy 1 1 lN methyl N 3 nitro methylphenoxycarbonyl amino propyl dibenz b,f oxepin g. 3 ethyl 8 hydroxy 1 1 ss methylamino ethylthio dibenz b,f oxepin h. 4 methoxy 7 hydroxy 1 1 z diethylamino propylthio dibenz b,f oxepin i. 6 hydroxy 2 methyithio l l L ethylamino butylthio dibenz b,f oxepin j. 3 ethylsulfonyl 9 hydroxy 1 1 8 dimethylamino ethylthio dibenz b,f oxepin k. 4 ethylsulfinyl 7 hydroxy 1 1 r dimethylamino propylthio dibenz b,f oxepin 2 amino 8 hydroxy 1 1 ethylamino ethylthio dibenz b,f oxepin m. 7 hydroxy 2 nitro 1 1 ss methylamino ethylthio dibenz b,f oxepin n. 2,7 dihydroxy 1 1 ss dimethylamino ethylthio b,foxepin. Effective amounts of the compounds of the present invention may be administered to a subject by any one of various methods, for example, orally as in capsules or tablets, parenterally in the form of sterile solutions or suspensions, and in some cases intravenously in the form of sterile solutions. The aminoalkylthio hydroxydibenzoxepins of the present invention, while effective themselves, may be formulated and administered in the form of their pharmaceutically acceptable addition salts for purposes of ability, convenience, crystallization, increased solubility and the like. Preferred pharmaceutically acceptable addition salts include salts of mineral acids, for example, hydrochloric acid, sulfuric acid, nitric acid and the like, salts of monobasic carboxylic acids such as, for example, acetic acid, propionic acid and the like, salts of dibasic carboxylic acids such as, for example, maleic acid, fumaric acid and the like, and salts of tribasic carboxylic acids such as, for example, carboxysuccinic acid, citric acid and the like. Effective quantities of the compounds of the invention may be administered orally, for example, with an inert diluent or with an edible carrier. They may be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the aforesaid compounds may be incorporated with excipients and used in the form of tablets, troches, capsules, elixirs, suspensions, syrups, wafers, chewing gums and the like. These preparations should contain at least 0.5 of active compound, but may be varied depending upon the particular form and may conveniently be between 4 to about 70 of the weight of the unit. The amount of active compound in such composition is such that a suitable dosage will be obtained.Preferred compositions and preparations according to the present invention are prepared so that an oral dosage unit form contains between 1.0300 milligrams of the active compound. The tablets, pills, capsules, troches and the like may also contain the following ingredients a binder such as microcrystalline cellulose, gum tragancanth or gelatin an excipient such as starch or lactose, a disintegrating agent such as alginic acid, corn starch and the like a lubricant such as magnesium stearate a glidant such as colloidal silicon dioxide and a sweetening agent such as sucrose or saccharin or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring may be added When the dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier such as a fatty oil. Other dosage unit forms may contain other various materials which modify the physical form of the dosage unit, for example, as coating. Thus, tablets or pills may be coated with sugar, shellac, or other enteric coating agents.A syrup may contain, inaddition to the active compounds, sucrose as a sweetening agent and certain preservatives, dyes and colorings and flavors. Materials used in preparing these various compositions should be pharmaceutically pure and non toxic in the amounts used. For the purposes of parenteral therapeutic administration, the active compounds of the invention may be incorporated into a solution or suspension.These preparations should contain at least 0.1 of active compound, but may be varied between 0.5 and about 50 of the weight thereof. The amount of active compounds in such compositions is such that a suitable dosage will be obtained. Preferred compositions and preparations according to the present invention are prepared so that a parenteral dosage unit contains between 0.5 to 100 milligrams of active compound. The solutions or suspensions may also include the following components a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents antibacterial agents such as benzyl alcohol or methyl parabens antioxidants such as ascorbic acid or sodium bisulfite chelating agents such as ethylenedi√†minetetraacetic acid buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. The parenteral preparation can be enclosed in ampules, disposable syringes or multiple dose vials made of glass or plastic. The following examples are for illustrative purposes only and are not to be construed as limiting the invention.EXAMPLE 1 2 Fluoro 8 hydroxy 1 1 ,i N methyl N phenoxycarbonylami no ethylthio dibenz b,f oxepin A solution of 2.1 g of 2 fiuoro 8 methoxy 1 1 8 N methyl N phenoxycarbonyl ethylthio dibenz b,f oxepin in 10 ml of dichloromethane was cooled while 6 ml of a stock solution of 1 M boron tribromide in dichloromethane was added dropwise.Stirring was continued at room temperature for 16 hrs before the reaction mixture was quenched with 100 ml of water. The organics were extracted into ether, washed and dried over anhydrous magnesium sulfate. Removal of the solvent under reduced pressure left an oil which was passed through a column of silica gel packed in ether and eluted with ether to yield 1.65 g 58 of product, m.p. 109 C, after trituration with hexane.ANALYSIS Calculated for C24H2eFNO4S 65.891C 4.61H 3.2e N Pound 66.29to 4.810H 2.99 NEXAMPLE 2 2 Fluoro 8 hydroxy 1 1 ss methylamino ethylthio dibenz b,f oxepin A mixture of 1.5 g of 2 fluoro 8 hydroxy 1 1 ss N methyl N phenoxycarbonylamino ethylthio dibenz b,f oxepin, 3.0 g of 85 potassium hydroxide in 10 ml of ethylene glycol was stirred at 165 C for 1 hr. The cooled solution was diluted with water and made acidic pH 2 with conc hydrochloric acid. The mixture was extracted with ether, the aqueous solution was basified with potassium carbonate solution and extracted exhaustively with chloroform. The combined organic extracts were washed with water, dried over anhydrous magnesium sulfate and the solvent was removed in vacuo. Recrystallized from acetone hexane gave 750 mg 69.5 of product, mp 159 160 C. ANALYSIS Calculated for C17H16PNO2S 64.33 C 5.08 H 4.41 NPound 64.25 C 5.25 H 4.4lN EXAMPLE 3 2 Fluoro 7 hydroxy 1 1 ss methylamino ethylthio dibenz b,f oxepin To a solution of 1.0 g of 2 fluoro 7 methoxy 1 1 ss N methyl N phenoxycarbonyl ethylthio dibenz b,f oxepin in 5 ml of dichloromethane was added dropwise 4 ml of 1 M boron tribromide in dichloromethane. After stirring at room temperature for 15 hrs, the mixture was equilibrated with 20 ml of ether and 10 ml of 2N hydrochloric acid. Stirring was continued for 1 hr, and layers were separated.The organic phase was washed with water, dried over anhydrous magnesium sulfate and concentrated to give 2 fiuoro 7 hydroxy 1 1 ss N methyl N phenoxycarbonylamino ethylthio dibenz b,f oxepin as an oil. The carbamate 0.5 g was dissolved in 3 ml of ethylene glycol and heated with 1.0 g of potassium hydroxide in 2 ml of water under nitrogen at 1500C for 3 hrs. The cooled mixture was diluted with 100 ml of water and acidified to pH 2 with conc hydrochloric acid. The neutral and acidic components were removed by ether extraction, and the aqueous solution was saturated with solid potassium carbonate. The mixture was extracted with a large excess of chloroform, washed and dried. Evaporation of solvent gave a 185 mg 27 of product. An analytical sample, prepared by recrystallization from acetone hexane, had m.p. 181 182 C. ANALYSIS . Calculated for C17Hl6FNO2S E4.33 C 5.S8 R 4.41 N Found 63.91 C 9.18 H 4.54 N